This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2006 Sep 1;24(25):4054-5.

doi: 10.1200/JCO.2006.07.4658.

What is the right dose? The elusive optimal biologic dose in phase I clinical trials

PMID: 16943522
DOI: 10.1200/JCO.2006.07.4658

Editorial

What is the right dose? The elusive optimal biologic dose in phase I clinical trials

Alex A Adjei. J Clin Oncol. 2006.

. 2006 Sep 1;24(25):4054-5.

doi: 10.1200/JCO.2006.07.4658.

Author

PMID: 16943522
DOI: 10.1200/JCO.2006.07.4658

No abstract available

PubMed Disclaimer

Comment on

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. Carducci MA, et al. J Clin Oncol. 2006 Sep 1;24(25):4092-9. doi: 10.1200/JCO.2005.05.3447. J Clin Oncol. 2006. PMID: 16943527 Clinical Trial.

Similar articles

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. Carducci MA, et al. J Clin Oncol. 2006 Sep 1;24(25):4092-9. doi: 10.1200/JCO.2005.05.3447. J Clin Oncol. 2006. PMID: 16943527 Clinical Trial.
Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects.
Welch PA, Sinha VP, Cleverly AL, Darstein C, Flanagan SD, Musib LC. Welch PA, et al. J Clin Pharmacol. 2007 Sep;47(9):1138-51. doi: 10.1177/0091270007304775. J Clin Pharmacol. 2007. PMID: 17766700 Clinical Trial.
Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia.
Widmer N, Gotta V, Haouala A, Decosterd LA. Widmer N, et al. Leuk Res. 2010 Jun;34(6):698-9. doi: 10.1016/j.leukres.2009.12.009. Epub 2010 Jan 13. Leuk Res. 2010. PMID: 20074797 No abstract available.
Enzastaurin.
Ma S, Rosen ST. Ma S, et al. Curr Opin Oncol. 2007 Nov;19(6):590-5. doi: 10.1097/CCO.0b013e3282f10a00. Curr Opin Oncol. 2007. PMID: 17906457 Review.
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B. Strumberg D, et al. Oncologist. 2007 Apr;12(4):426-37. doi: 10.1634/theoncologist.12-4-426. Oncologist. 2007. PMID: 17470685 Review.

See all similar articles

Cited by

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope.
Ma S, Ji J, Tong Y, Zhu Y, Dou J, Zhang X, Xu S, Zhu T, Xu X, You Q, Jiang Z. Ma S, et al. Acta Pharm Sin B. 2022 Jul;12(7):2990-3005. doi: 10.1016/j.apsb.2022.02.022. Epub 2022 Feb 26. Acta Pharm Sin B. 2022. PMID: 35865099 Free PMC article. Review.
The emerging low-dose therapy for advanced cancers.
Satti J. Satti J. Dose Response. 2009 Mar 24;7(3):208-20. doi: 10.2203/dose-response.08-010.Satti. Dose Response. 2009. PMID: 19809540 Free PMC article.
PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy.
Kelm JM, Pandey DS, Malin E, Kansou H, Arora S, Kumar R, Gavande NS. Kelm JM, et al. Mol Cancer. 2023 Mar 30;22(1):62. doi: 10.1186/s12943-022-01707-5. Mol Cancer. 2023. PMID: 36991452 Free PMC article. Review.
Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.
Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, van 't Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber GM, Wimana Z, Gebhart G. Bartelink IH, et al. Clin Pharmacol Ther. 2019 Jul;106(1):148-163. doi: 10.1002/cpt.1211. Epub 2018 Oct 6. Clin Pharmacol Ther. 2019. PMID: 30107040 Free PMC article. Review.
Identification of New Small-Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation.
Peng L, Zhang Z, Lei C, Li S, Zhang Z, Ren X, Chang Y, Zhang Y, Xu Y, Ding K. Peng L, et al. ACS Med Chem Lett. 2019 Apr 12;10(5):767-772. doi: 10.1021/acsmedchemlett.9b00025. eCollection 2019 May 9. ACS Med Chem Lett. 2019. PMID: 31097997 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database